Well if they're not using their own technology for most of their tests it isn't just a marketing problem, it's an image problem that would lead investors to believe they don't have faith in their own product. Secondly, according to the article, their protocols even when using conventional machines differ from the norm in that they are forced to dilute samples to increase sample volume because they take less blood to begin with. This is generally accepted as being a less accurate practice.